Is Pfizer (PFE) One of the Best Fortune 500 Dividend Stocks to Invest in Right Now?

With an annual dividend yield of 6.37%, Pfizer Inc. (NYSE:PFE) is included among the 10 Best Fortune 500 Dividend Stocks to ...

Should You Forget Pfizer and Buy This Pharma Stock Instead?

Pfizer has a higher-yielding dividend, but it may not be safe. AbbVie has the better path to growth in 2026. But when you ...

Pfizer protects $6.4bn heart disease blockbuster from generics, for now

Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.

Pfizer Could Surprise Again This Earnings Season (Preview)

Pfizer continues delivering consistent earnings beats, driven by cost-cutting initiatives and improving margins. Learn more ...

AbbVie vs. Pfizer: One Pharma Dividend Has a Moat — The Other Is Praying for a Pipeline Hit

AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE) both reported fourth quarter earnings in early February. AbbVie posted record net ...
Rolling Out

Pfizer beats Q3 estimates by impressive 32%

Pfizer delivered a significant earnings surprise in its third-quarter results, demonstrating the pharmaceutical giant’s resilience amid a challenging year for its stock performance. The company’s ...
Hosted on MSN

Pfizer-Cipla settlement delays Vyndamax generics until 2031

Pfizer has settled patent disputes with Cipla, Dexcel Pharma, and Hikma Pharmaceuticals over Vyndamax, extending U.S. exclusivity to June 1, 2031. The deal averts earlier generic entry and stabilizes ...
Morningstar

Pfizer won its fight to buy an obesity-drug maker. It took an extra $1.7 billion and a phone call.

Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, with more money and help from the Trump administration Pfizer won its fight to ...